Go to
JCI Insight
Abstract
In humans, the biological limitations to cardiac regenerative growth create both a clinical imperative — to offset cell death in acute ischemic injury and chronic heart failure — and a clinical opportunity; that is, for using cells, genes, and proteins to rescue cardiac muscle cell number or in other ways promote more efficacious cardiac repair. Recent experimental studies and early-phase clinical trials lend credence to the visionary goal of enhancing cardiac repair as an achievable therapeutic target.
Authors
Stefanie Dimmeler, Andreas M. Zeiher, Michael D. Schneider
Figure 3
Options:
View larger image
(or click on image)
Download as PowerPoint
Mobilization and homing. After intravascular delivery or mobilization from bone marrow, progenitor cells are targeted to the sites of injury by multiple signals. Homing is mediated by a multistep process including the initial adhesion, transmigration, and invasion. Molecular mechanisms contributing to these individual steps are indicated but likely vary depending on the cell type and model. EPO, erythropoietin; MCP-1, monocyte chemoattractant protein–1.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)